A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma.
作者： F. Perez-Zincer , T. Olencki , G.T. Budd , D. Peereboom , P. Elson
关键词:
摘要: Introduction: Recombinant humaninterferon-α2b (rHuIFN-α2b)and Interleukin-2 have limitedeffectiveness in the treatment ofmetastatic renal cell carcinoma (MRCC).Gemcitabine (Gemzar®) is also reported tohave activity against MRCC, and recent invitro, nude mice xenografts, humandata suggests increased ofgemcitabine when combined withIFN-α2b.
springer.com
sci-hub.se 参考文章(28)
Steven A. Rosenberg, Gwendolyn Fyfe, Gwendolyn Fyfe, Richard I. Fisher, Mario Sznol, David R. Parkinson, David R. Parkinson, High-dose aldesleukin in renal cell carcinoma: long-term survival update The cancer journal from Scientific American. ,vol. 3, ,(1997)
J A Neidhart, S A Anderson, J E Harris, J J Rinehart, J Laszlo, F H Dexeus, L H Einhorn, D L Trump, P W Benedetto, R L Tuttle, Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. Journal of Clinical Oncology. ,vol. 9, pp. 832- 836 ,(1991) , 10.1200/JCO.1991.9.5.832
N. H. Bander, G. Gastl, D. M. Nanus, L. M. Pfeffer, C. L. Finstad, A. P. Albino, Anti-Proliferative and Anti-Tumor Effect of α-Interferon in Renal Cell Carcinoma: Correlation with the Expression of a Kidney Associated Differentiation Glycoprotein Basic and Clinical Research on Renal Cell Carcinoma. ,vol. 50, pp. 115- 120 ,(1992) , 10.1007/978-3-642-76863-7_11
J A Sparano, S Wadler, R B Diasio, R Zhang, Z Lu, E L Schwartz, A Einzig, P H Wiernik, Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. Journal of Clinical Oncology. ,vol. 11, pp. 1609- 1617 ,(1993) , 10.1200/JCO.1993.11.8.1609
J L Abbruzzese, R Grunewald, E A Weeks, D Gravel, T Adams, B Nowak, S Mineishi, P Tarassoff, W Satterlee, M N Raber, A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. Journal of Clinical Oncology. ,vol. 9, pp. 491- 498 ,(1991) , 10.1200/JCO.1991.9.3.491
L M Minasian, R J Motzer, L Gluck, M Mazumdar, V Vlamis, S E Krown, Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. Journal of Clinical Oncology. ,vol. 11, pp. 1368- 1375 ,(1993) , 10.1200/JCO.1993.11.7.1368
W.C. Mertens, E.A. Eisenhauer, M. Moore, P. Venner, D. Stewart, A. Muldal, D. Wong, Gemcitabine in advanced renal cell carcinoma A phase II study of the National Cancer Institute of Canada Clinical Trials Group Annals of Oncology. ,vol. 4, pp. 331- 332 ,(1993) , 10.1093/OXFORDJOURNALS.ANNONC.A058494
D Rohde, M Goertz, H Hayn, U Cremer, G Jakse, Interferon-alpha and gemcitabine (2',2'-difluorodeoxycytidine) in adult and pediatric renal tumors. International Journal of Oncology. ,vol. 11, pp. 623- 627 ,(1997) , 10.3892/IJO.11.3.623
D Rohde, M Goertz, J Blatter, G Jakse, The efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) and vinblastine combined with interferon in nude mice xenografts of human renal cell carcinoma. International Journal of Oncology. ,vol. 12, pp. 1367- 1439 ,(1998) , 10.3892/IJO.12.6.1367
M. Golimbu, A. Tessler, P. Joshi, S. Al-Askari, A. Sperber, P. Morales, Renal cell carcinoma: Survival and prognostic factors Urology. ,vol. 27, pp. 291- 301 ,(1986) , 10.1016/0090-4295(86)90300-6